NEUCA S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 938 PLN | +3.99% |
|
+2.85% | +1.41% |
| May. 23 | NEUCA S.A. announces an Equity Buyback for 120,000 shares, for PLN 120 million. | CI |
| May. 23 | NEUCA S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 13.02B 3.29B | Sales 2025 * | 13.69B 3.46B | Capitalization | 4.03B 1.02B |
|---|---|---|---|---|---|
| Net income 2024 * | 188M 47.5M | Net income 2025 * | 230M 58.11M | EV / Sales 2024 * | 0.33 x |
| Net Debt 2024 * | 278M 70.23M | Net Debt 2025 * | 169M 42.77M | EV / Sales 2025 * | 0.31 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 4,633 |
| Yield 2024 * |
1.66% | Yield 2025 * |
2.22% | Free-Float | 35.53% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.77% | ||
| 1 week | -3.63% | ||
| Current month | -1.10% | ||
| 1 month | -1.85% | ||
| 3 months | +2.04% | ||
| 6 months | +6.75% | ||
| Current year | -2.49% |
1 week
896.00
932.00
1 month
896.00969.00
Current year
790.00969.00
1 year
630.00969.00
3 years
527.00969.00
5 years
279.00969.00
10 years
182.10969.00
| Managers | Title | Age | Since |
|---|---|---|---|
Piotr Sucharski
CEO | Chief Executive Officer | - | 00-12-31 |
| Founder | - | 89-12-31 | |
Grzegorz Dzik
DFI | Director of Finance/CFO | - | 10-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 89-12-31 | |
| Director/Board Member | 72 | 09-06-15 | |
| Founder | - | 89-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 7 M€ | +5.21% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 938 | +3.99% | 3 500 |
| 24-06-04 | 902 | -0.77% | 618 |
| 24-06-03 | 909 | -0.33% | 425 |
| 24-05-31 | 912 | 0.00% | 339 |
| 24-05-29 | 912 | -2.56% | 421 |
Delayed Quote Warsaw S.E., June 04, 2024 at 11:55 am EDT
More quotes
Neuca SA is a Poland-based company, which operates in the healthcare market. The Company is mainly involved in the distribution of drugs to pharmacies. It also operates in other sectors of the health market, such as production of drugs, supplements and cosmetics under its own brand, clinical trials, telemedicine, Information Technology (IT) solutions and e-commerce in the health care industry.
Sector
Pharmaceuticals
Calendar
2024-06-11
- Ex-dividend day for final dividend
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
902
PLN
Average target price
974.7
PLN
Spread / Average Target
+8.06%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.49% | 1.02B | |
| +23.92% | 74.58B | |
| -2.46% | 23.95B | |
| +10.52% | 8.52B | |
| +6.36% | 8.55B | |
| -21.71% | 7.85B | |
| +11.90% | 5.18B | |
| +2.27% | 4.17B | |
| -4.23% | 4.06B | |
| +5.42% | 3.89B |
- Stock Market
- Equities
- NEU Stock
